Collagen Tiles Could Prevent Brain Cancer Recurrence
A clinical trial has found that placing radioactive tiles into the brain cavity at tumor removal dramatically cuts recurrence and extends survival. The ROADS trial, led by MD Anderson Cancer Center, was presented at the 2026 American Society of Clinical Oncology meeting.
It is the first randomized Phase 3 study to directly compare this approach with postoperative stereotactic radiation therapy, conducted across multiple centers. The study was sponsored by GT Medical Technologies, maker of the FDA-cleared brachytherapy device used in the trial.
Left untreated with radiation, the surgical cavity shows regrowth in 50% to 60% of patients, making some form of postoperative treatment essential. One year after surgery, just 1.3% of tile-group patients saw cancer return at the resection site, versus 15.4% among patients in the standard treatment arm.
Median overall survival reached 42.5 months against 17.6 months for the standard group, a difference the researchers described as far exceeding expectations. The tile group achieved this while receiving no separate outpatient radiation sessions at all.
Each tile is roughly postage-stamp-sized and carries cesium-131 seeds distributed at regular intervals through a collagen matrix. The device is FDA-cleared and manufactured by GT Medical Technologies. Surgeons apply them directly to the cavity walls, targeting the margin where residual cancer cells most commonly hide after tumor removal.
The seeds deliver a therapeutic dose across the weeks that follow, losing intensity rapidly over distance and leaving most surrounding healthy tissue unaffected. One advantage over standard care is timing: the current approach involves a median 32-day wait between surgery and the start of radiation. Standard radiation delivers full benefit only when started promptly, yet roughly one in five patients never receive it due to recovery complications and scheduling.
That gap also delays access to systemic treatments, potentially allowing cancer elsewhere to progress in the meantime. With the tile approach, radiation is delivered in full during the same procedure, closing that gap entirely.
Jeffrey Weinberg, professor of neurosurgery at MD Anderson, and Thomas Beckham, assistant professor of CNS radiation oncology, co-led the trial. Weinberg said that administering radiation intraoperatively alongside dose concentration at the cavity wall appeared to drive the improvement in both tumor control and patient survival.
Beckham said the faster timeline helped patients stay on top of their broader cancer care, a result that exceeded the team’s expectations. The trial found no rise in serious adverse effects, and radiation necrosis occurred at comparable rates in both groups.
Patients using the tile method finish their full radiation course during the initial operation, meaning they can resume broader cancer treatment weeks sooner. The researchers expect the data to drive TBRT toward mainstream clinical use. Future work will examine whether similar gains can be achieved in different cancer settings.
This development offers hope that brain cancers could be successfully treated as more advancements are made over the coming years. Given that other for-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also making progress in their drug development programs, brain malignancies could see their notoriety tamed by these new therapeutics.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
A clinical trial has found that placing radioactive tiles into the brain cavity at tumor removal dramatically cuts recurrence and extends survival. The ROADS trial, led by MD Anderson Cancer Center, was presented at the 2026 American Society of Clinical Oncology meeting.
It is the first randomized Phase 3 study to directly compare this approach with postoperative stereotactic radiation therapy, conducted across multiple centers. The study was sponsored by GT Medical Technologies, maker of the FDA-cleared brachytherapy device used in the trial.
Left untreated with radiation, the surgical cavity shows regrowth in 50% to 60% of patients, making some form of postoperative treatment essential. One year after surgery, just 1.3% of tile-group patients saw cancer return at the resection site, versus 15.4% among patients in the standard treatment arm.
Median overall survival reached 42.5 months against 17.6 months for the standard group, a difference the researchers described as far exceeding expectations. The tile group achieved this while receiving no separate outpatient radiation sessions at all.
Each tile is roughly postage-stamp-sized and carries cesium-131 seeds distributed at regular intervals through a collagen matrix. The device is FDA-cleared and manufactured by GT Medical Technologies. Surgeons apply them directly to the cavity walls, targeting the margin where residual cancer cells most commonly hide after tumor removal.
The seeds deliver a therapeutic dose across the weeks that follow, losing intensity rapidly over distance and leaving most surrounding healthy tissue unaffected. One advantage over standard care is timing: the current approach involves a median 32-day wait between surgery and the start of radiation. Standard radiation delivers full benefit only when started promptly, yet roughly one in five patients never receive it due to recovery complications and scheduling.
That gap also delays access to systemic treatments, potentially allowing cancer elsewhere to progress in the meantime. With the tile approach, radiation is delivered in full during the same procedure, closing that gap entirely.
Jeffrey Weinberg, professor of neurosurgery at MD Anderson, and Thomas Beckham, assistant professor of CNS radiation oncology, co-led the trial. Weinberg said that administering radiation intraoperatively alongside dose concentration at the cavity wall appeared to drive the improvement in both tumor control and patient survival.
Beckham said the faster timeline helped patients stay on top of their broader cancer care, a result that exceeded the team’s expectations. The trial found no rise in serious adverse effects, and radiation necrosis occurred at comparable rates in both groups.
Patients using the tile method finish their full radiation course during the initial operation, meaning they can resume broader cancer treatment weeks sooner. The researchers expect the data to drive TBRT toward mainstream clinical use. Future work will examine whether similar gains can be achieved in different cancer settings.
This development offers hope that brain cancers could be successfully treated as more advancements are made over the coming years. Given that other for-profit firms like CNS Pharmaceuticals Inc. (NASDAQ: CNSP) are also making progress in their drug development programs, brain malignancies could see their notoriety tamed by these new therapeutics.
Please see full terms of use and disclaimers on the TinyGems website applicable to all content provided by TinyGems, wherever published or re-published: https://www.TinyGems.net/Disclaimer
